PDS Biotechnology Corporation (PDSB)
NASDAQ: PDSB · Real-Time Price · USD
0.9022
-0.0477 (-5.02%)
At close: Jan 26, 2026, 4:00 PM EST
0.8801
-0.0221 (-2.45%)
After-hours: Jan 26, 2026, 4:29 PM EST
PDS Biotechnology Employees
PDS Biotechnology had 24 employees as of December 31, 2024. The number of employees decreased by 1 or -4.00% compared to the previous year.
Employees
24
Change (1Y)
-1
Growth (1Y)
-4.00%
Revenue / Employee
n/a
Profits / Employee
-$1,453,539
Market Cap
49.37M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 24 | -1 | -4.00% |
| Dec 31, 2023 | 25 | -1 | -3.85% |
| Dec 31, 2022 | 26 | 4 | 18.18% |
| Dec 31, 2021 | 22 | 7 | 46.67% |
| Dec 31, 2020 | 15 | 0 | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Aligos Therapeutics | 70 |
| Q32 Bio | 26 |
| NeurAxis | 21 |
| iBio, Inc. | 20 |
| ABVC BioPharma | 19 |
| Instil Bio | 14 |
| OS Therapies | 5 |
| Lite Strategy | 4 |
PDSB News
- 4 days ago - PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101 - GlobeNewsWire
- 17 days ago - PDS Biotech Announces FDA Alignment on use of Progression Free Survival (PFS) as Primary Endpoint - GlobeNewsWire
- 6 weeks ago - PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan - GlobeNewsWire
- 7 weeks ago - PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”) - GlobeNewsWire
- 2 months ago - PDS Biotechnology Corporation (PDSB) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update - GlobeNewsWire
- 2 months ago - PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering - GlobeNewsWire
- 2 months ago - PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025 - GlobeNewsWire